FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385477043> ?p ?o ?g. }

• W4385477043 endingPage "9" @default.
• W4385477043 startingPage "1" @default.
• W4385477043 abstract "AbstractCytarabine-containing chemoimmunotherapy followed by autologous transplantation and rituximab maintenance achieves durable remissions for most patients with mantle cell lymphoma (MCL). However, patients with TP53-mutated disease have poor outcomes with standard approaches. We previously reported that allogeneic stem cell transplantation (alloSCT) achieved durable remissions in MCL, however follow-up among patients with TP53-mutated disease was limited. Here we report extended follow-up of the overall cohort (n = 36) and TP53-mutated subset (n = 13) (median follow-up 10.8 and 4.2 years, respectively). Estimated overall survival was 56% at 10 years for the overall cohort and 59% at 4 years for the TP53-mutated subset. Among patients with TP53-mutated disease, no relapses occurred beyond 6 months post-transplant. Survival after post-alloSCT disease relapse was poor (median 2.1 years). These data confirm that alloSCT can be curative in MCL, including patients with TP53-mutated disease, and should be considered for earlier utilization in this subgroup for whom conventional chemoimmunotherapy is ineffective.Keywords: Neoplasialymphoma and hodgkin diseasemarrow and stem cell transpantationclinical resultsneoplasiamolecular genetics Author contributionsT.E.L., D.R. and A.K. conceived of the project and designed the study; T.E.L, E.R.S.C, M.D., C.S.T., J.F.S, A.B., D.R., A.K were responsible for patient care; P.B contributed molecular data; T.E.L., and E.R.S.C. collected the data; T.E.L. analyzed the data; P.B. performed and analyzed genomic data; T.E.L. and E.R.S.C wrote the first version of the manuscript; and all authors reviewed the data and contributed to critical revision of the manuscript.Disclosure statementTEL is an employee of the Walter and Eliza Hall Institute of Medical Research, which receives milestone and royalty payments related to venetoclax. TEL is a recipient of a share in royalty payments paid to the Walter and Eliza Hall Institute of Medical Research. TEL has received honoraria from AbbVie. ERSC’s research is funded by Arnold Ventures. MD has received research funding from Roche, Novartis, Gilead, and Takeda, and has received honoraria from Roche, AbbVie, GenMab, Novartis, Kite, Gilead, and Bristol Myers Squibb. CST has received honoraria and research funding from AbbVie and Janssen and honoraria from BeiGene. JFS receives research funding from AbbVie, Genentech, Celgene, and Janssen and is an advisory board member for and has received honoraria from AbbVie, Acerta, Celgene, Genentech, Janssen, Roche, Sunesis, and Takeda. AK has received honoraria from Janssen, Celgene, Kyowa, Kirin, and Amgen. AB has received honoraria from Novartis, Amgen, Astellas, Abbvie and speaker fees from Amgen. The remaining authors declare no competing financial interests.Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article." @default.
• W4385477043 created "2023-08-03" @default.
• W4385477043 creator A5017442411 @default.
• W4385477043 creator A5018838899 @default.
• W4385477043 creator A5027391845 @default.
• W4385477043 creator A5034517642 @default.
• W4385477043 creator A5055934687 @default.
• W4385477043 creator A5068409419 @default.
• W4385477043 creator A5081326206 @default.
• W4385477043 creator A5088177143 @default.
• W4385477043 creator A5090592945 @default.
• W4385477043 date "2023-08-02" @default.
• W4385477043 modified "2023-09-25" @default.
• W4385477043 title "Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in <i>TP53</i>-mutated disease" @default.
• W4385477043 cites W2047164612 @default.
• W4385477043 cites W2065574306 @default.
• W4385477043 cites W2333943209 @default.
• W4385477043 cites W2470400696 @default.
• W4385477043 cites W2749289906 @default.
• W4385477043 cites W2760635695 @default.
• W4385477043 cites W2773054919 @default.
• W4385477043 cites W2795301499 @default.
• W4385477043 cites W2891539827 @default.
• W4385477043 cites W2900472144 @default.
• W4385477043 cites W2905570061 @default.
• W4385477043 cites W2986093834 @default.
• W4385477043 cites W2989894850 @default.
• W4385477043 cites W3014583893 @default.
• W4385477043 cites W3029266545 @default.
• W4385477043 cites W3047197230 @default.
• W4385477043 cites W3081707124 @default.
• W4385477043 cites W3093292179 @default.
• W4385477043 cites W3186545390 @default.
• W4385477043 cites W3195225489 @default.
• W4385477043 cites W3210991186 @default.
• W4385477043 cites W4220900334 @default.
• W4385477043 cites W4225633026 @default.
• W4385477043 cites W4281622098 @default.
• W4385477043 cites W4281687647 @default.
• W4385477043 cites W4281901970 @default.
• W4385477043 cites W4281959249 @default.
• W4385477043 cites W4283381496 @default.
• W4385477043 cites W4310161073 @default.
• W4385477043 cites W4310162498 @default.
• W4385477043 cites W4318928313 @default.
• W4385477043 cites W4319457643 @default.
• W4385477043 doi "https://doi.org/10.1080/10428194.2023.2241095" @default.
• W4385477043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37531077" @default.
• W4385477043 hasPublicationYear "2023" @default.
• W4385477043 type Work @default.
• W4385477043 citedByCount "0" @default.
• W4385477043 crossrefType "journal-article" @default.
• W4385477043 hasAuthorship W4385477043A5017442411 @default.
• W4385477043 hasAuthorship W4385477043A5018838899 @default.
• W4385477043 hasAuthorship W4385477043A5027391845 @default.
• W4385477043 hasAuthorship W4385477043A5034517642 @default.
• W4385477043 hasAuthorship W4385477043A5055934687 @default.
• W4385477043 hasAuthorship W4385477043A5068409419 @default.
• W4385477043 hasAuthorship W4385477043A5081326206 @default.
• W4385477043 hasAuthorship W4385477043A5088177143 @default.
• W4385477043 hasAuthorship W4385477043A5090592945 @default.
• W4385477043 hasConcept C126322002 @default.
• W4385477043 hasConcept C143998085 @default.
• W4385477043 hasConcept C2777525834 @default.
• W4385477043 hasConcept C2779338263 @default.
• W4385477043 hasConcept C2780653079 @default.
• W4385477043 hasConcept C2780790343 @default.
• W4385477043 hasConcept C28328180 @default.
• W4385477043 hasConcept C2911091166 @default.
• W4385477043 hasConcept C54355233 @default.
• W4385477043 hasConcept C71924100 @default.
• W4385477043 hasConcept C72563966 @default.
• W4385477043 hasConcept C86803240 @default.
• W4385477043 hasConcept C90924648 @default.
• W4385477043 hasConceptScore W4385477043C126322002 @default.
• W4385477043 hasConceptScore W4385477043C143998085 @default.
• W4385477043 hasConceptScore W4385477043C2777525834 @default.
• W4385477043 hasConceptScore W4385477043C2779338263 @default.
• W4385477043 hasConceptScore W4385477043C2780653079 @default.
• W4385477043 hasConceptScore W4385477043C2780790343 @default.
• W4385477043 hasConceptScore W4385477043C28328180 @default.
• W4385477043 hasConceptScore W4385477043C2911091166 @default.
• W4385477043 hasConceptScore W4385477043C54355233 @default.
• W4385477043 hasConceptScore W4385477043C71924100 @default.
• W4385477043 hasConceptScore W4385477043C72563966 @default.
• W4385477043 hasConceptScore W4385477043C86803240 @default.
• W4385477043 hasConceptScore W4385477043C90924648 @default.
• W4385477043 hasLocation W43854770431 @default.
• W4385477043 hasLocation W43854770432 @default.
• W4385477043 hasOpenAccess W4385477043 @default.
• W4385477043 hasPrimaryLocation W43854770431 @default.
• W4385477043 hasRelatedWork W1997629499 @default.
• W4385477043 hasRelatedWork W2007548746 @default.
• W4385477043 hasRelatedWork W2102241654 @default.
• W4385477043 hasRelatedWork W2112679438 @default.
• W4385477043 hasRelatedWork W21424034 @default.
• W4385477043 hasRelatedWork W2403773722 @default.
• W4385477043 hasRelatedWork W2412433018 @default.

• next